This Science News Wire page contains a press release issued by an organization and is provided to you "as is" with little or no review from Science X staff.

386 Million EUR Research Programme on Neurodegeneration Featured at Alzheimer Europe Conference

January 20th, 2021
386 Million EUR Research Programme on Neurodegeneration Featured at Alzheimer Europe Conference
Neuronet logo Credit: Neuronet Consortium

In 2019, the Neuronet Sessions introduced the projects of the Innovative Medicines Initiative (IMI) neurodegeneration portfolio to a broad audience composed of patients, caregivers, patient associations, researchers and clinicians.

This year, we expanded the focus of the event, titled "Working together to address common challenges for European neurodegeneration research". Over the course of four parallel sessions, we showcased the work of IMI neurodegeneration projects on data sharing, ethics and regulatory/HTA interactions, and hosted presentations from early-career investigators working on these projects. In addition we held a roundtable discussion, during which project leaders discussed the challenges experienced by public-private partnerships during the COVID-19 pandemic, and how research will evolve in the critical post-COVID period.

We are pleased to provide you with recordings of the 2020 Neuronet Sessions, which were held as part of the 30th Alzheimer Europe Virtual Annual Conference between 20-22 October, under the banner "Dementia in a Changing World".

Follow this link for to access the recordings: https://www.imi-neuronet.org/2020-virtual/

More information:
www.imi-neuronet.org/386-milli … r-europe-conference/

Provided by Alzheimer Europe

Citation: 386 Million EUR Research Programme on Neurodegeneration Featured at Alzheimer Europe Conference (2021, January 20) retrieved 25 April 2024 from https://sciencex.com/wire-news/372575493/386-million-eur-research-programme-on-neurodegeneration-featured.html
This document is subject to copyright. Apart from any fair dealing for the purpose of private study or research, no part may be reproduced without the written permission. The content is provided for information purposes only.